具有抑制 Ganoderma lucidum 脂质积累的作用的三类植物
Lu Chai1, Xiao-Cui Liu1, Zhou-Wei Wu1
1State Key Laboratory of Phytochemistry and Natural Medicines, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming 650201, Yunnan, People's Republic of China; University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China.
Fitoterapia
|May 5, 2025
概括
这项研究从Ganoderma lucidum中分离出了新型的lanostane triterpenoids,其中一些显示出对肝细胞中脂质积累的抑制作用. 结构-活性分析强调了开发新的抗肥胖化合物的潜力.
科学领域:
- 自然产品化学 自然产品化学
- 药理学 药理学是指药理学的学科.
- 药用化学 医学化学
背景情况:
- (Ganoderma lucidum) 是一种具有丰富使用历史的药用.
- 三聚类是一种多样化的自然产品类别,具有各种各样的生物活动.
- 了解G. lucidum的化学成分和生物活性对于其治疗应用至关重要.
研究的目的:
- 从种植的Ganoderma lucidum中分离和表征新型的兰诺斯坦型三基.
- 评估分离化合物对油酸诱导的HepG2细胞中的脂质积累的抑制作用.
- 为了研究这些三类化合物的结构-活性关系,关于它们的降脂潜力.
主要方法:
- 使用色谱技术从Ganoderma lucidum果实体中分离化合物.
- 通过综合光谱方法 (NMR,MS等) 阐明分离化合物的结构. ) 的情况.
- 在实验室中评估了用油酸 (OA) 刺激的 HepG2 细胞中脂质积累抑制.
主要成果:
- 发现了8种新的拉诺斯坦类型三基 (1-8) 和27种已知的类似物 (9-35).
- 甘酸D (1) 和E (2) 具有罕见的五环三基结构,具有四个环.
- 化合物7,9和29显示中度抑制脂质积累;化合物9显示剂量依赖的抑制.
- 与C24和C30类似物相比,降解的C27诺特类药物显示出增强的疗效.
结论:
- 种植的Ganoderma lucidum是一种有价值的结构多样化的lanostane三烯酸的来源.
- 来自G. lucidum的特异性三类化合物具有调节脂质代谢的潜力.
- 结构修改,特别是侧链降解,可以增强这些化合物的抗脂积累活性.
更多相关视频
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
475
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
475
Enzyme Inhibition
77.5K
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
77.5K
Dipeptidyl Peptidase 4 Inhibitors
140
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
140
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
488
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
488
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
128
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
128
Indirect-Acting Cholinergic Agonists: Mechanism of Action
1.5K
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
1.5K


